At this stage it remains speculative, as to whether short term changes in the TTR microheterogeneity may be indicative of an individual susceptibility to destabilizing modifications in TTR, or whether transient changes might be of long term consequence for the affected ICU patient with regard to amyloidosis, Alzheimer’s disease, or the occurrence of other neurological disorders. The gene discussed is TTR; the disease is Alzheimer disease.